Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast‐like synoviocytes
Tóm tắt
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology characterized by degradation of cartilage and bone, accompanied by unimpeded proliferation of synoviocytes of altered phenotype. In the present study, we investigated the involvement of the glucagon‐like peptide 1 (GLP‐1) receptor on human fibroblast‐like synoviocytes (FLS) in the pathogenesis of RA using the selective GLP‐1 agonist exenatide, a licensed drug used for the treatment of type 2 diabetes. Our results indicate that exenatide may play a role in regulating tumor necrosis factor‐α‐induced mitochondrial dysfunction by increasing mitochondrial membrane potential, oxidative stress by reducing the production of reactive oxygen species, the expression of NADPH oxidase 4, expression of matrix metalloproteinase (MMP)‐3 and MMP‐13, release of proinflammatory cytokines including interleukin‐1β (IL‐1β), IL‐6, monocyte chemoattractant protein‐1, and high‐mobility group protein 1, as well as activation of the p38/nuclear factor of κ light polypeptide gene enhancer in B‐cells inhibitor, α/nuclear factor κB signaling pathway in primary human RA FLS. These positive results indicate that exenatide may have potential as a therapeutic agent for the treatment and prevention of RA. © 2019 IUBMB Life, 9999(9999):1–9, 2019
Từ khóa
Tài liệu tham khảo
Yesil S., 2018, Exenatide reduces oxidative stress and cell death in testis in iron overload rat model, Exp. Ther. Med., 16, 4349
Tang Z., 2018, Exendin‐4 reverses endothelial dysfunction in mice fed a high‐cholesterol diet by a GTP cyclohydrolase‐1/tetrahydrobiopterin pathway, Mol. Med. Rep., 18, 3350
Chiquette E., 2012, Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers, Vasc. Health Risk Manag., 8, 621
Fernandes J. C., 2002, The role of cytokines in osteoarthritis pathophysiology, Biorheology, 39, 237
Berenbaum F. Bougault C. andAttali C.(2017)U.S. Patent No. 9 592 272. Washington DC: U.S. Patent and Trademark Office.
Haack T. Wagner M. Henkel B. Stengelin S. Evers A. et al. (2017)U.S. Patent Application No. 14/569 326.